Table 3.

Statistically significant (P < 0.05) interactionsa between antioxidant and vitamin E transport SNPs and vitamin E supplementation interactions (P < 0.05) for the risk of high-grade prostate cancer (N = 1,124)

Genotype frequencyHR (95% CI) high-grade cancer
GeneGenotypeN (%) casesN (%) controlsPlacebo armVitamin E armPb
SEC14L2rs5753106
AA106 (59.2%)543 (57.6%)1.00.98 (0.64–1.49)0.008
AG65 (36.3%)347 (36.8%)0.74 (0.44–1.24)1.25 (0.80–1.97)
GG8 (4.5%)52 (5.5%)0.14 (0.02–0.99)1.57 (0.63–3.91)
TTPArs12679996
CC69 (38.5%)361 (38.9%)1.02.29 (1.32–3.97)0.001
CT77 (43.0%)426 (46.0%)1.34 (0.74–2.40)1.70 (0.98–2.94)
TT33 (18.4%)140 (15.1%)2.76 (1.44–5.29)1.33 (0.60–2.97)
rs4606052
CC62 (35.4%)271 (29.9%)1.02.25 (1.26–4.03)0.007
CT68 (38.9%)434 (48.0%)0.97 (0.53–1.79)1.27 (0.71–2.25)
TT45 (25.7%)200 (22.1%)2.02 (1.06–3.82)1.38 (0.69–2.75)
  • aFull results for all analyzed SNP x vitamin E assignment interactions are presented in Supplementary Table S3.

  • bP for test for interaction between SNP and selenium assignment for the outcome of risk of high-grade prostate cancer.